455 patients with a-fib or VTE were randomized to pharmacogenetic-directed warfarin therapy for the first 5 days or a 3-day loading regimen. Genotype-based dosing resulted in a 10% higher rate of being in the therapeutic range, a shorter time to reach a therapeutic INR, and fewer instances of excessive anticoagulation.
A Randomized Trial of Genotype-Guided Dosing of Warfarin
Submitted by: Erica Curcio
Source: New England Journal of Medicine
Keywords:
Author(s): M Pirmohamed and others for the EU-PACT Group